MCID: OVR011
MIFTS: 28

Ovarian Mucinous Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Adenocarcinoma

MalaCards integrated aliases for Ovarian Mucinous Adenocarcinoma:

Name: Ovarian Mucinous Adenocarcinoma 12 15 73
Mucinous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3606
NCIt 50 C5243
UMLS 73 C1335167

Summaries for Ovarian Mucinous Adenocarcinoma

MalaCards based summary : Ovarian Mucinous Adenocarcinoma, also known as mucinous carcinoma of ovary, is related to teratoma and mucinous adenocarcinoma. An important gene associated with Ovarian Mucinous Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Gastric cancer and Statin Pathway - Generalized, Pharmacokinetics. The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary and endothelial.

Related Diseases for Ovarian Mucinous Adenocarcinoma

Diseases related to Ovarian Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 teratoma 30.0 CDX2 KRT7
2 mucinous adenocarcinoma 28.7 CDX2 KRT20 KRT7 MUC2
3 cystic teratoma 28.0 CDX2 KRT20 KRT7 MUC2
4 mucinous adenocarcinoma of ovary 11.6
5 ovary neuroendocrine neoplasm 10.5 CDX2 KRT7
6 mucinous adenofibroma 10.5 CDX2 KRT7
7 anus adenocarcinoma 10.5 CDX2 KRT7
8 bronchiolo-alveolar adenocarcinoma 10.5 CDX2 KRT7
9 nasal cavity adenocarcinoma 10.5 CDX2 KRT7
10 mucinous ovarian cystadenoma 10.5 CDX2 KRT7
11 anal canal adenocarcinoma 10.5 CDX2 KRT7
12 anus cancer 10.4 CDX2 KRT7
13 renal adenoma 10.4 AMACR KRT7
14 clear cell papillary renal cell carcinoma 10.3 AMACR KRT7
15 nephrogenic adenoma 10.3 AMACR KRT7
16 metanephric adenoma 10.3 AMACR KRT7
17 adenocarcinoma 10.3
18 kidney benign neoplasm 10.3 AMACR KRT7
19 intestinal obstruction 10.3 CDX2 KRT7
20 urethral diverticulum 10.3 AMACR KRT7
21 collecting duct carcinoma 10.3 AMACR KRT7
22 cystic basal cell carcinoma 10.3 KRT20 KRT7
23 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
24 transverse colon cancer 10.3 KRT20 KRT7
25 ovarian large-cell neuroendocrine carcinoma 10.3 KRT20 KRT7
26 eyelid neoplasm 10.2 KRT20 KRT7
27 malignant syringoma 10.2 KRT20 KRT7
28 krukenberg carcinoma 10.2 KRT20 KRT7
29 large intestine adenocarcinoma 10.2 KRT20 KRT7
30 villous adenoma 10.2 CDX2 KRT20
31 linitis plastica 10.2 KRT20 KRT7
32 lung acinar adenocarcinoma 10.2 KRT20 KRT7
33 small cell carcinoma of the bladder 10.2 KRT20 KRT7
34 adenoid squamous cell carcinoma 10.2 KRT20 KRT7
35 eccrine sweat gland neoplasm 10.2 KRT20 KRT7
36 vulval paget's disease 10.2 KRT20 KRT7
37 intratubular embryonal carcinoma 10.2 KRT20 KRT7
38 meibomian cyst 10.2 KRT20 KRT7
39 bladder lymphoma 10.2 KRT20 KRT7
40 papillary serous adenocarcinoma 10.2 KRT20 KRT7
41 medulloepithelioma 10.2 KRT20 KRT7
42 glycogen-rich clear cell breast carcinoma 10.2 KRT20 KRT7
43 renal pelvis carcinoma 10.2 KRT20 KRT7
44 paget disease, extramammary 10.2 KRT20 KRT7
45 spindle cell carcinoma 10.2 AMACR KRT7
46 lymphoepithelioma-like carcinoma 10.2 KRT20 KRT7
47 dermoid cyst 10.2 KRT20 KRT7
48 infiltrative basal cell carcinoma 10.2 KRT20 KRT7
49 immune system organ benign neoplasm 10.2 KRT20 KRT7
50 thymus lipoma 10.2 KRT20 KRT7

Graphical network of the top 20 diseases related to Ovarian Mucinous Adenocarcinoma:



Diseases related to Ovarian Mucinous Adenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Adenocarcinoma

Drugs & Therapeutics for Ovarian Mucinous Adenocarcinoma

Drugs for Ovarian Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Carboplatin Approved Phase 3,Phase 1 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
6 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
7 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
8 Antibodies Phase 3,Phase 2,Phase 1
9 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
10 Antimitotic Agents Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
12 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
13 Immunoglobulin G Phase 3,Phase 2,Phase 1
14 Immunoglobulins Phase 3,Phase 2,Phase 1
15 Mitogens Phase 3,Phase 2,Phase 1
16 Carotenoids Phase 3
17 Micronutrients Phase 3
18 Trace Elements Phase 3
19 taxane Phase 3
20
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
21
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
22
Pembrolizumab Approved Phase 2 1374853-91-4
23
nivolumab Approved Phase 2 946414-94-4
24
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
25 Alkylating Agents Phase 2
26 Antineoplastic Agents, Alkylating Phase 2
27 Antirheumatic Agents Phase 2
28 Immunosuppressive Agents Phase 2
29
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
30
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
31
Veliparib Investigational Phase 1 912444-00-9 11960529
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
4 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
6 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
7 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
8 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
9 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
10 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
11 QUILT-3.017: Study of NEO-201 in Solid Tumors Not yet recruiting NCT03476681 Phase 1 NEO-201
12 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Search NIH Clinical Center for Ovarian Mucinous Adenocarcinoma

Genetic Tests for Ovarian Mucinous Adenocarcinoma

Anatomical Context for Ovarian Mucinous Adenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Adenocarcinoma:

41
Ovary, Endothelial

Publications for Ovarian Mucinous Adenocarcinoma

Articles related to Ovarian Mucinous Adenocarcinoma:

# Title Authors Year
1
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
2
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions. ( 26576867 )
2015
3
Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. ( 25197383 )
2014
4
Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. ( 24487473 )
2014
5
A case of ovarian mucinous adenocarcinoma in a premenarcheal girl. ( 22016113 )
2012
6
Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. ( 21556953 )
2011
7
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. ( 19926591 )
2010
8
Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. ( 15721446 )
2005
9
An ovarian mucinous adenocarcinoma arising from mature cystic teratoma associated with respiratory type tissue: a case report. ( 15656343 )
2004
10
Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. ( 9158713 )
1997

Variations for Ovarian Mucinous Adenocarcinoma

Cosmic variations for Ovarian Mucinous Adenocarcinoma:

9
(show top 50) (show all 204)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 4
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 4
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 4
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 4
5 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 4
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 4
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 4
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 4
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 4
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 4
11 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 4
12 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 4
13 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 4
14 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 4
15 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 4
16 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 4
17 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 4
18 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 4
19 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 4
20 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 4
21 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 4
22 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 4
23 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 4
24 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 4
25 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 4
26 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 4
27 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 4
28 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 4
29 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 4
30 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 4
31 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 4
32 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 4
33 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 4
34 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 4
35 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 4
36 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 4
37 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 4
38 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 4
39 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 4
40 COSM20640 WEE2 ovary,NS,carcinoma,mucinous carcinoma c.1193G>A p.R398H 7:141724247-141724247 3
41 COSM20669 ULK1 ovary,NS,carcinoma,mucinous carcinoma c.868G>A p.V290M 12:131910720-131910720 3
42 COSM6923559 TSC1 ovary,NS,carcinoma,mucinous carcinoma c.1997+1G>A p.? 9:132905580-132905580 3
43 COSM20712 TRRAP ovary,NS,carcinoma,mucinous carcinoma c.5786G>T p.R1929L 7:98955228-98955228 3
44 COSM10801 TP53 ovary,NS,carcinoma,mucinous carcinoma c.404G>A p.C135Y 17:7675208-7675208 3
45 COSM10660 TP53 ovary,NS,carcinoma,mucinous carcinoma c.818G>A p.R273H 17:7673802-7673802 3
46 COSM10758 TP53 ovary,NS,carcinoma,mucinous carcinoma c.659A>G p.Y220C 17:7674872-7674872 3
47 COSM10662 TP53 ovary,NS,carcinoma,mucinous carcinoma c.743G>A p.R248Q 17:7674220-7674220 3
48 COSM11089 TP53 ovary,NS,carcinoma,mucinous carcinoma c.584T>C p.I195T 17:7674947-7674947 3
49 COSM10705 TP53 ovary,NS,carcinoma,mucinous carcinoma c.586C>T p.R196* 17:7674945-7674945 3
50 COSM10704 TP53 ovary,NS,carcinoma,mucinous carcinoma c.844C>T p.R282W 17:7673776-7673776 3

Expression for Ovarian Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Adenocarcinoma.

Pathways for Ovarian Mucinous Adenocarcinoma

GO Terms for Ovarian Mucinous Adenocarcinoma

Sources for Ovarian Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....